SYTL2

SYTL2 (Slp2-a) is a membrane- and vesicle-associated effector that couples Rab27-dependent vesicular trafficking to actin- and Rap-based control of cell shape, spreading, and motility (PMID:24284068, PMID:37029109). Its two C2 domains act through separable mechanisms: the C2B domain recruits Rap1 GAPs to the plasma membrane of renal epithelial cells to inactivate Rap signaling and its downstream effector ezrin, thereby restraining cell spreading and controlling epithelial cell size in a Rab27-independent manner (PMID:24284068). In cancer settings SYTL2 acts as a pro-migratory and pro-metastatic factor: in prostate cancer it binds the actin-bundling protein FSCN1 and protects it from proteasomal degradation, stabilizing FSCN1 to drive pseudopodia formation, migration, invasion, and lymph node metastasis (PMID:37147713). Together with Rab27a it facilitates trafficking of vesicles carrying angiogenic factors (Pdgfb, Vwf) to support tumor vascularization in alveolar soft part sarcoma, where it is driven as a super-enhancer target of the ASPSCR1::TFE3 fusion (PMID:37029109). SYTL2 expression is itself epigenetically regulated, with promoter CpG methylation governing its levels in ovarian carcinoma (PMID:27220283).

1. 2008 Low

   Established a candidate compensatory trafficking role for SYTL2 by linking it with Rab27A in a disease context where the question was how membrane repair pathways adapt to dysferlin loss.

   Evidence mRNA expression profiling of dysferlin-deficient (LGMD2B) patient muscle biopsies with pathway analysis

   PMID:18832576

   Open questions at the time

   • Correlative expression only, no direct functional reconstitution of a SYTL2-Rab27A complex in muscle repair
   • Did not demonstrate vesicular trafficking activity for SYTL2 directly
   • Causal contribution to inflammation not tested
2. 2013 High

   Resolved how SYTL2 controls epithelial cell size, showing a Rab27-independent C2B-domain mechanism that recruits Rap1 GAPs to inactivate Rap-ezrin signaling and restrain cell spreading.

   Evidence siRNA knockdown, domain mutagenesis, pharmacological epistasis (miglustat), Drosophila ortholog rescue, and fractionation in MDCK II cells; with correlative ezrin-activity data in the pcy polycystic kidney model

   PMID:24284068

   Open questions at the time

   • Identity of the specific Rap1 GAP(s) recruited not fully defined
   • Mechanism of C2B-domain membrane targeting not structurally resolved
   • Disease model link to polycystic kidney disease is correlative
3. 2016 Medium

   Showed SYTL2 is a migration/invasion-promoting factor whose expression is set epigenetically, addressing how its oncogenic levels are controlled.

   Evidence Overexpression with migration/invasion assays, bisulfite sequencing of promoter CpGs, pharmacological demethylation and HDAC inhibition, and xenograft model in ovarian carcinoma cells

   PMID:27220283

   Open questions at the time

   • Molecular effector through which SYTL2 drives migration not identified in this context
   • No domain-level mechanistic dissection
   • Single cell-line system
4. 2023 High

   Defined a molecular mechanism for SYTL2-driven metastasis: it binds and stabilizes FSCN1 against proteasomal degradation to promote pseudopodia and invasion.

   Evidence Reciprocal Co-IP, protein stability assays, 3D migration and invasion assays, popliteal lymph node metastasis mouse model, and FSCN1 rescue experiments in prostate cancer

   PMID:37147713

   Open questions at the time

   • Mechanism by which SYTL2 binding blocks FSCN1 ubiquitination/degradation not defined
   • Domain of SYTL2 mediating FSCN1 binding not mapped
   • Whether Rab27 binding contributes to this function unknown
5. 2023 Medium

   Connected SYTL2 to tumor angiogenesis, showing it works with Rab27a to traffic angiogenic-factor vesicles and is itself a super-enhancer target of the ASPSCR1::TFE3 fusion.

   Evidence Epigenomic CRISPR/dCas9 screening, super-enhancer mapping, vesicle trafficking assays, and in vivo tumor model in alveolar soft part sarcoma

   PMID:37029109

   Open questions at the time

   • Trafficking role inferred from co-upregulation and angiogenic factor levels rather than direct vesicle-tracking of SYTL2
   • Direct cargo selectivity for Pdgfb/Vwf vesicles not established
   • Single lab and tumor type

• How SYTL2's distinct C2A/Rab27-dependent trafficking activity and C2B/Rap-GAP and FSCN1-stabilizing activities are integrated or switched between epithelial homeostasis and cancer remains unresolved.
• No unified model linking the Rab27-binding and FSCN1-stabilizing functions
• Structural basis of C2-domain partner selection not determined
• Physiological (non-cancer) role of the FSCN1 interaction untested